scholarly journals Substance use disorders in adolescent and young adult relatives of probands with bipolar disorder: What drives the increased risk?

2017 ◽  
Vol 78 ◽  
pp. 130-139 ◽  
Author(s):  
Leslie A. Hulvershorn ◽  
Jennifer King ◽  
Patrick O. Monahan ◽  
Holly C. Wilcox ◽  
Philip B. Mitchell ◽  
...  
2020 ◽  
Author(s):  
Scott C Adams ◽  
Jennifer Herman ◽  
Iliana C Lega ◽  
Laura Mitchell ◽  
David Hodgson ◽  
...  

Abstract Survivors of adolescent and young adult cancers (AYAs) often live 50 to 60 years beyond their diagnosis. This rapidly growing cohort is at increased risk for cancer- and treatment-related late effects that persist for decades into survivorship. Recognition of similar issues in pediatric cancer survivors has prompted the development of evidence-based guidelines for late effects screening and care. However, corresponding evidence-based guidelines for AYAs have not been developed. We hosted an AYA survivorship symposium for a large group of multidisciplinary AYA stakeholders (approximately 200 were in attendance) at Princess Margaret Cancer Centre (Toronto, ON) to begin addressing this disparity. The following overview briefly summarizes and discusses the symposium’s stakeholder-identified high-priority targets for late effects screening and care, and highlights knowledge gaps to direct future research in the field of AYA survivorship. This overview, while not exhaustive, is intended to stimulate clinicians to consider these high-priority screening and care targets when seeing survivors in clinical settings and, ultimately, support the development of evidence-based ‘late effects’ screening and care guidelines for AYAs.


2007 ◽  
Vol 62 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Timothy E. Wilens ◽  
Joseph Biederman ◽  
Joel Adamson ◽  
Michael Monuteaux ◽  
Aude Henin ◽  
...  

Author(s):  
Sarah C Snow ◽  
Gregg C Fonarow ◽  
Joseph A Ladapo ◽  
Donna L Washington ◽  
Katherine Hoggatt ◽  
...  

Background: Several cardiotoxic substances contribute to the development of heart failure (HF). The burden of comorbid substance use disorders (SUD) among patients with HF is under-characterized. Objectives: To describe the national burden of comorbid SUD (tobacco, alcohol, or drug use disorders) among hospitalized HF patients in the U.S. Methods: We used data from the 2014 National Inpatient Sample to calculate the proportion of hospitalizations for a primary HF admission with tobacco, alcohol, or drug use disorder diagnoses, accounting for demographic factors. Drug use disorder analysis was further sub-divided into specific illicit substance categories. Results: There were a total of 989,080 HF hospitalizations of which 35.3% (n=348,995) had a documented SUD. Tobacco use disorder (TUD) was most common (n= 327,220, 33.1%) followed by drug use disorder (DUD) (n=34,600, 3.5%) and alcohol use disorder (AUD) (n=34,285, 3.5%). Female sex was associated with less TUD (OR 0.59; 95% CI, 0.58-0.60), AUD (OR 0.23; 95% CI, 0.22-0.25) or DUD (OR 0.58; 95% CI 0.55-0.62). Tobacco, alcohol, cocaine, and opioid use disorders were highest among HF patients age 45 to 55, while cannabis and amphetamine use was highest in those <45 years. Native American race (versus White) was associated with increased risk of AUD (OR 1.67; 95% CI 1.27-2.20). Black race was associated with increased risk of AUD (OR 1.09; 95% CI 1.02-1.16) or DUD (OR 1.63; 95% CI 1.53-1.74). Medicaid insurance (versus Medicare) was associated with greater TUD (OR 1.27; 95% CI 1.23-1.32), AUD (OR 1.74; 95% CI 1.62-1.87), and DUD (OR 2.15; 95% CI 2.01-2.30). Decreasing quartiles of median household income were associated with increasing SUD. Conclusions: Comorbid SUD disproportionately affects certain HF populations, including men, younger age groups, lower SES patients, and race/ethnic minorities. Further research on interventions to improve prevention and treatment of SUD among hospitalized HF patients are needed given the high rates of SUD in this population. Systematically screening hospitalized HF patients for SUD may reveal opportunities for treatment and secondary prevention.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Peter B. Barr ◽  
Albert Ksinan ◽  
Jinni Su ◽  
Emma C. Johnson ◽  
Jacquelyn L. Meyers ◽  
...  

Author(s):  
TIMOTHY E. WILENS ◽  
JOSEPH BIEDERMAN ◽  
RACHAEL B. MILLSTEIN ◽  
JANET WOZNIAK ◽  
AMY L. HAHESY ◽  
...  

2018 ◽  
Vol 5 (2) ◽  
pp. 110-119 ◽  
Author(s):  
Stephanie Carreiro ◽  
Peter R. Chai ◽  
Jennifer Carey ◽  
Jeffrey Lai ◽  
David Smelson ◽  
...  

Author(s):  
Kristina Caudle ◽  
B.J. Casey

Drug and alcohol dependence affects millions each year. Adolescence is a period of increased risk for substance use disorders. Understanding how the brain is changing during this developmental window relative to childhood and adulthood and how these changes vary across individuals is critical for predicting risk of later substance abuse and dependence. This chapter provides an overview of recent human imaging and animal studies of brain development focusing on changes in corticostriatal circuitry that has been implicated in addiction. Behavioral, clinical, and neurobiological evidence is provided to help elucidate who may be most at risk for developing a substance abuse problem and whenthey may be most vulnerable.


2019 ◽  
Vol 256 ◽  
pp. 348-357
Author(s):  
R. Icick ◽  
I. Melle ◽  
B. Etain ◽  
P.A. Ringen ◽  
S.R. Aminoff ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document